What is Estrella Immunopharma's operating income?

Estrella Immunopharma's total operating income in 2024 was -$7.31 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $7.31 million

Estrella Immunopharma (ESLAW) Financials

$0.08 0.00 (-6.00%)

As of 07/16/2026 12:58 PM Eastern

Compare

Annual Income Statements for Estrella Immunopharma

This table shows Estrella Immunopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	6/30/2023	6/30/2024
Net Income / (Loss) Attributable to Common Shareholders	-0.25	-1.00	-11	-7.31
Consolidated Net Income / (Loss)	-0.25	-1.00	-11	-7.31
Net Income / (Loss) Continuing Operations	-0.25	-1.00	-11	-7.31
Total Pre-Tax Income	-0.25	-0.92	-11	-7.31
Total Operating Income	-0.25	-1.57	-11	-7.31
Total Gross Profit	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00
Total Operating Expenses	0.25	1.57	11	7.31
Selling, General & Admin Expense	0.18	1.37	0.66	3.20
Research & Development Expense	-	-	10	4.11
Total Other Income / (Expense), net	0.00	0.65	0.00	0.00
Income Tax Expense	0.00	0.08	0.00	0.00
Basic Earnings per Share	($0.76)	($0.38)	($36.35)	($0.27)
Weighted Average Basic Shares Outstanding	0.00	5.76M	305.75K	27.10M
Weighted Average Diluted Shares Outstanding	0.00	5.76M	-	36.19M
Weighted Average Basic & Diluted Shares Outstanding	5.85M	2.33M	-	36.19M

This table shows Estrella Immunopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	12/31/2023	9/30/2023	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Consolidated Net Income / (Loss)	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Net Income / (Loss) Continuing Operations	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Total Pre-Tax Income	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Total Operating Income	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	1.02	1.87	3.95	3.38	2.10	5.54	4.80	2.29
Selling, General & Admin Expense	0.95	1.39	0.42	0.55	0.69	0.88	0.65	0.89
Research & Development Expense	0.08	0.48	3.53	2.83	1.41	4.66	4.15	1.40
Total Other Income / (Expense), net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Tax Expense	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Basic Earnings per Share	($0.03)	($1.78)	($0.11)	($0.09)	($0.06)	($0.15)	($0.13)	($0.05)
Weighted Average Basic Shares Outstanding	35.20M	1.05M	36.38M	36.21M	36.19M	36.17M	37.10M	42.12M
Diluted Earnings per Share	-	($1.78)	($0.11)	($0.09)	($0.06)	($0.15)	($0.13)	($0.05)
Weighted Average Diluted Shares Outstanding	36.61M	1.05M	36.38M	36.21M	36.19M	36.17M	37.10M	42.12M
Weighted Average Basic & Diluted Shares Outstanding	36.61M	35.20M	-	36.38M	36.17M	37.07M	37.77M	43.03M

This table details how cash moves in and out of Estrella Immunopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	6/30/2023	6/30/2024
Net Change in Cash & Equivalents	0.48	-0.44	-1.61	1.69
Net Cash From Operating Activities	-0.32	-1.04	-1.34	-16
Net Cash From Continuing Operating Activities	-0.32	-1.04	-1.34	-16
Net Income / (Loss) Continuing Operations	-0.25	-1.00	-11	-7.31
Consolidated Net Income / (Loss)	-0.25	-1.00	-11	-7.31
Non-Cash Adjustments To Reconcile Net Income	-0.00	-0.65	0.41	1.19
Changes in Operating Assets and Liabilities, net	-0.07	0.61	9.37	-9.95
Net Cash From Investing Activities	-45	36	-0.27	4.96
Net Cash From Continuing Investing Activities	-45	36	-0.27	4.96
Other Investing Activities, net	-45	36	-0.27	4.96
Net Cash From Financing Activities	46	-36	0.00	13
Net Cash From Continuing Financing Activities	46	-36	0.00	13
Repayment of Debt	-0.30	0.00	0.00	9.70
Repurchase of Common Equity	-0.58	-36	0.00	-1.88
Issuance of Debt	0.30	0.55	0.00	0.30
Issuance of Preferred Equity	-	-	0.00	9.02
Other Financing Activities, net	43	0.00	0.00	-4.35
Cash Interest Paid	-	-	0.00	0.00
Cash Income Taxes Paid	-	-	0.00	0.00

This table details how cash moves in and out of Estrella Immunopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	12/31/2023	9/30/2023	6/30/2024	9/30/2024	6/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Net Change in Cash & Equivalents	1.51	20	-25	-2.37	-0.56	-0.50	0.90	0.31	0.54
Net Cash From Operating Activities	-11	-0.28	-4.25	-2.22	-0.29	-0.47	-0.41	-0.73	-6.70
Net Cash From Continuing Operating Activities	-11	-0.27	-4.25	-2.22	-0.29	-0.46	-0.41	-0.73	-6.70
Net Income / (Loss) Continuing Operations	-2.83	-1.87	-2.55	-3.38	-3.95	-2.10	-5.54	-4.80	-2.29
Consolidated Net Income / (Loss)	-2.83	-1.87	-2.55	-3.38	-3.95	-2.10	-5.54	-4.80	-2.29
Non-Cash Adjustments To Reconcile Net Income	1.30	1.19	-1.19	-	3.50	0.16	0.16	0.15	0.26
Changes in Operating Assets and Liabilities, net	-9.74	0.40	-0.51	1.16	0.16	1.48	4.97	3.92	-4.66
Net Cash From Investing Activities	4.88	-0.11	0.11	-	-	0.00	-	-	0.00
Net Cash From Continuing Investing Activities	-0.19	-0.11	0.11	-	-	0.00	-	-	0.00
Net Cash From Financing Activities	13	20	-20	-0.15	-0.27	-0.03	1.31	1.04	7.24
Net Cash From Continuing Financing Activities	13	20	-20	-0.15	-0.27	-0.03	1.31	1.04	7.24
Repurchase of Common Equity	-	0.00	-0.35	-0.15	-0.27	-0.03	-0.04	-0.01	-0.76
Issuance of Common Equity	-	-	-	-	-	0.00	-	1.05	8.00
Other Financing Activities, net	-4.40	0.73	-	-	-	0.00	-	-	0.00
Cash Interest Paid	-	0.00	-	-	-	0.00	-	-	0.00
Cash Income Taxes Paid	-	0.00	0.00	-	0.00	0.00	0.00	-	0.00

This table presents Estrella Immunopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	6/30/2023	12/31/2024	12/31/2025
Total Assets	46	9.72	3.03	3.14	3.18
Total Current Assets	0.62	0.05	2.75	1.64	1.68
Cash & Equivalents	0.48	0.04	2.48	0.92	1.38
Prepaid Expenses	0.14	0.01	0.00	0.72	0.29
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	45	9.67	0.28	1.50	1.50
Other Noncurrent Operating Assets	45	9.67	0.28	1.50	1.50
Total Liabilities & Shareholders' Equity	46	9.72	3.03	3.14	3.18
Total Liabilities	1.62	2.65	9.77	3.00	14
Total Current Liabilities	0.07	1.07	9.76	3.00	14
Accounts Payable	0.00	0.33	9.73	0.21	0.79
Accrued Expenses	-	-	0.04	2.79	12
Other Current Liabilities	0.00	0.50	0.00	0.00	0.36
Total Noncurrent Liabilities	1.55	1.58	0.01	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-1.01	-2.26	-6.74	0.14	-10
Total Preferred & Common Equity	-1.01	-2.26	-12	0.14	-10
Preferred Stock	0.00	0.00	5.00	0.00	0.00
Total Common Equity	-1.01	-2.26	-12	0.14	-10
Common Stock	0.00	0.00	0.45	25	27
Retained Earnings	-1.01	-2.26	-12	-24	-37
Treasury Stock	-	-	0.00	-0.57	-0.60

This table presents Estrella Immunopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q1 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	12/31/2023	9/30/2023	3/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	9.45	27	8.63	2.44	2.98	3.52	3.66
Total Current Assets	9.45	22	8.63	0.94	1.48	2.02	2.16
Cash & Equivalents	9.05	22	4.73	0.42	1.32	1.63	1.93
Prepaid Expenses	0.40	0.14	3.91	0.52	0.16	0.40	0.23
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	0.00	5.07	0.00	1.50	1.50	1.50	1.50
Other Noncurrent Operating Assets	0.00	5.07	0.00	1.50	1.50	1.50	1.50
Total Liabilities & Shareholders' Equity	9.45	27	8.63	2.44	2.98	3.52	3.66
Total Liabilities	0.40	17	0.14	4.28	9.08	13	8.93
Total Current Liabilities	0.40	17	0.14	4.28	9.08	13	8.93
Accounts Payable	0.35	12	0.09	0.13	0.12	0.08	0.19
Accrued Expenses	0.01	0.02	0.17	4.14	8.77	13	8.27
Other Current Liabilities	-	-	0.00	-	0.19	0.39	0.47
Total Noncurrent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9.05	10	8.49	-1.83	-6.09	-9.84	-5.27
Total Preferred & Common Equity	9.05	10	8.49	-1.83	-6.09	-9.84	-5.27
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	9.05	10	8.49	-1.83	-6.09	-9.84	-5.27
Common Stock	24	24	24	25	26	27	35
Retained Earnings	-15	-14	-16	-26	-32	-36	-39
Treasury Stock	-	-	-0.08	-0.60	-0.60	-0.60	-0.60

This table displays calculated financial ratios and metrics derived from Estrella Immunopharma's official financial filings.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	6/30/2023	6/30/2024
DEI Shares Outstanding	5,849,700.00	5,849,700.00	5,849,700.00	36,610,870.00
DEI Adjusted Shares Outstanding	5,849,700.00	5,849,700.00	5,849,700.00	36,610,870.00
DEI Earnings Per Adjusted Shares Outstanding	-0.04	-0.17	-1.90	-0.20
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-529.96%	-608.14%	34.23%
EBIT Growth	0.00%	-529.96%	-608.14%	34.23%
NOPAT Growth	0.00%	-529.96%	-608.14%	34.23%
Net Income Growth	0.00%	-302.11%	-1,015.79%	34.21%
EPS Growth	0.00%	50.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	-230.17%	-28.00%	-1,102.61%
Free Cash Flow Firm Growth	0.00%	0.00%	-75.95%	-269.35%
Invested Capital Growth	0.00%	-83.80%	-230.56%	101.17%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	73.50%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	73.50%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	73.50%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	83.17%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	12.80%	6.76%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	-83.82%	0.00%	0.00%
Profitability Metrics	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	108.81%	100.00%	100.02%
Interest Burden Percent	99.43%	58.33%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-0.56%	-3.89%	-6,772.72%	592.27%
Cash Return on Invested Capital (CROIC)	0.00%	139.90%	0.00%	-13,373.16%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.01%	0.25%	288,857.14%	1,791.64%
Return on Equity Simple (ROE_SIMPLE)	24.62%	44.16%	94.65%	-171.10%
Net Operating Profit after Tax (NOPAT)	-0.17	-1.10	-7.78	-5.12
NOPAT Margin	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-15.31%	43.68%	-267.61%	-65.84%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-0.25	-1.57	-11	-7.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.25	-1.57	-11	-7.31
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	9.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	9.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.35	9.81	0.00	316.80
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	1.96	7.72	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00
Financial Leverage	-0.01	-0.01	-7.59	2.70
Leverage Ratio	1.04	1.08	38.85	-3.03
Compound Leverage Factor	1.03	0.63	38.85	-3.03
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	-74.16%	0.00%
Noncontrolling Interests to Total Capital	102.28%	131.90%	0.00%	0.00%
Common Equity to Total Capital	-2.28%	-31.90%	174.16%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00
Altman Z-Score	21.39	12.63	-16.63	117.25
Noncontrolling Interest Sharing Ratio	102.28%	106.36%	4,365.01%	-202.51%
Liquidity Ratios	-	-	-	-
Current Ratio	8.42	0.05	0.28	24.65
Quick Ratio	6.55	0.04	0.28	23.05
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	36	8.54	-14
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-
Invested Capital	44	7.08	-9.24	0.11
Invested Capital Turnover	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-37	-16	9.35
Enterprise Value (EV)	103	69	66	34
Market Capitalization	58	60	63	38
Book Value per Share	($0.17)	($0.39)	($2.01)	$0.16
Tangible Book Value per Share	($0.17)	($0.39)	($2.01)	$0.16
Total Capital	44	7.07	-6.74	4.27
Total Debt	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00
Net Debt	-0.48	-0.04	-2.48	-4.17
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.06	-1.06	-9.49	0.11
Debt-free Net Working Capital (DFNWC)	0.54	-1.02	-7.01	4.27
Net Working Capital (NWC)	0.54	-1.02	-7.01	4.27
Net Nonoperating Expense (NNE)	0.07	-0.10	3.33	2.19
Net Nonoperating Obligations (NNO)	-0.48	0.01	-2.50	-4.17
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.38)	$0.00	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	3.21M	5.76M	0.00	27.10M
Adjusted Diluted Earnings per Share	$0.00	($0.38)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	3.21M	5.76M	0.00	36.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.85M	2.33M	0.00	36.19M
Normalized Net Operating Profit after Tax (NOPAT)	-0.17	-1.10	-7.78	-5.12
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-234.13%	-3,625.42%	0.00%	-25.70%

This table displays calculated financial ratios and metrics derived from Estrella Immunopharma's official financial filings.

Metric	Q2 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	12/31/2023	9/30/2023	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
DEI Shares Outstanding	35,201,232.00	2,168,354.00	36,610,870.00	36,610,870.00	36,610,870.00	36,610,870.00	36,610,870.00	36,610,870.00
DEI Adjusted Shares Outstanding	35,201,232.00	2,168,354.00	36,610,870.00	36,610,870.00	36,610,870.00	36,610,870.00	36,610,870.00	36,610,870.00
DEI Earnings Per Adjusted Shares Outstanding	-0.03	-0.86	-0.11	-0.09	-0.06	-0.15	-0.13	-0.06
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	62.97%	31.76%	-286.96%	0.00%	-12.50%	-40.37%	-42.18%	-8.92%
EBIT Growth	62.97%	31.76%	-286.96%	0.00%	-12.50%	-40.37%	-42.18%	-8.92%
NOPAT Growth	62.97%	31.76%	-286.96%	0.00%	-12.50%	-40.37%	-42.18%	-8.92%
Net Income Growth	62.97%	31.76%	-287.12%	0.00%	-12.50%	-40.34%	-42.18%	-8.92%
EPS Growth	0.00%	0.00%	0.00%	0.00%	96.63%	-36.36%	-44.44%	16.67%
Operating Cash Flow Growth	-971.69%	0.19%	62.27%	-121.64%	-69.33%	90.24%	67.20%	-1,337.40%
Free Cash Flow Firm Growth	214.50%	-49.33%	-123.04%	0.00%	-162.53%	129.40%	0.00%	130.40%
Invested Capital Growth	-121.21%	-265.42%	0.00%	0.00%	80.86%	0.00%	-418.00%	-219.55%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	62.77%	0.00%	-111.14%	14.50%	0.00%	-163.46%	13.40%	0.00%
EBIT Q/Q Growth	62.77%	0.00%	-111.14%	14.50%	0.00%	-163.46%	13.40%	0.00%
NOPAT Q/Q Growth	62.77%	0.00%	-111.14%	14.50%	0.00%	-163.46%	13.40%	0.00%
Net Income Q/Q Growth	62.77%	0.00%	-111.23%	14.54%	0.00%	-163.50%	13.41%	0.00%
EPS Q/Q Growth	0.00%	0.00%	93.82%	18.18%	0.00%	-150.00%	13.33%	0.00%
Operating Cash Flow Q/Q Growth	-3,986.22%	-536.36%	-1,444.72%	47.84%	-59.85%	10.97%	-75.31%	0.00%
Free Cash Flow Firm Q/Q Growth	50.27%	0.00%	-168.33%	100.00%	0.00%	132.13%	231.60%	0.00%
Invested Capital Q/Q Growth	-229.93%	0.00%	100.00%	0.00%	0.00%	-229.04%	-54.67%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.04%	100.00%	100.00%	100.02%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-10.07%	-119.97%	0.00%	0.00%	-183.18%	149.96%	1,574.90%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	3.61%	-52.98%	0.00%	0.00%	-183.18%	149.96%	1,574.90%	0.00%
Return on Equity Simple (ROE_SIMPLE)	15.84%	-101.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.71	-1.31	-2.76	-2.36	-1.47	-3.88	-3.36	-1.60
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-23.65%	-5.16%	0.00%	-20.72%	-5.67%	-252.78%	-44.20%	-58.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-27.83%	80.45%	63.68%	34.17%	30.44%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.02	-1.87	-3.95	-3.38	-2.10	-5.54	-4.80	-2.29
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.01	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	2.01	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.07	-1.27	0.00	-0.58	-2.70	0.22	4.86	0.33
Leverage Ratio	1.31	2.17	0.00	1.02	3.62	-0.49	-9.06	-0.86
Compound Leverage Factor	1.31	2.17	0.00	1.02	3.62	-0.49	-9.06	-0.86
Debt to Total Capital	0.00%	2.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	2.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	-74.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	174.16%	97.11%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.03	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	2.13	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.04	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	3.05	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-7.12	-0.02	0.00	0.00	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	135.87%	55.84%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.28	1.29	0.00	62.34	0.22	0.16	0.15	0.24
Quick Ratio	0.25	1.28	0.00	34.13	0.10	0.15	0.12	0.22
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	52	18	-12	0.00	-11	3.53	12	3.34
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	-9.24	-12	0.00	3.60	-2.25	-7.41	-11	-7.20
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-53	-19	9.24	0.00	9.52	-7.41	-15	-4.95
Enterprise Value (EV)	42	-1.59	0.00	0.00	0.00	0.00	0.00	0.00
Market Capitalization	39	20	38	0.00	0.00	0.00	0.00	0.00
Book Value per Share	($0.33)	$4.64	$0.00	$0.23	($0.05)	($0.17)	($0.27)	($0.13)
Tangible Book Value per Share	($0.33)	$4.64	$0.00	$0.23	($0.05)	($0.17)	($0.27)	($0.13)
Total Capital	-6.74	10	0.00	8.49	-1.83	-6.09	-9.84	-5.27
Total Debt	0.00	0.30	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2.48	-22	0.00	-4.73	-0.42	-1.32	-1.63	-1.93
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.49	-17	0.00	3.77	-3.75	-8.91	-13	-8.70
Debt-free Net Working Capital (DFNWC)	-7.01	5.30	0.00	8.49	-3.33	-7.59	-11	-6.77
Net Working Capital (NWC)	-7.01	5.00	0.00	8.49	-3.33	-7.59	-11	-6.77
Net Nonoperating Expense (NNE)	0.31	0.56	1.19	1.01	0.63	1.66	1.44	0.69
Net Nonoperating Obligations (NNO)	-2.50	-22	0.00	-4.89	-0.42	-1.32	-1.63	-1.93
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.03)	($1.78)	$0.00	($0.01)	$0.00	($0.15)	($0.13)	($0.05)
Adjusted Weighted Average Basic Shares Outstanding	35.20M	1.05M	0.00	35.52M	0.00	36.17M	37.10M	42.12M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.15)	($0.13)	($0.05)
Adjusted Weighted Average Diluted Shares Outstanding	36.61M	35.20M	0.00	36.38M	0.00	36.17M	37.10M	42.12M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.61M	35.20M	0.00	36.38M	0.00	37.07M	37.77M	43.03M
Normalized Net Operating Profit after Tax (NOPAT)	-0.71	-1.31	-2.76	-2.36	-1.47	-3.88	-3.36	-1.60
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2,023.28%	0.00%	8.89%	0.00%	-25.30%	-17.45%	-13.79%	0.00%

Financials Breakdown Chart

Estrella Immunopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Estrella Immunopharma's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

Estrella Immunopharma's net income appears to be on an upward trend, with a most recent value of -$7.31 million in 2024, rising from -$247.72 thousand in 2021. The previous period was -$11.11 million in 2023.

Estrella Immunopharma's total operating income in 2024 was -$7.31 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $7.31 million

Over the last 3 years, Estrella Immunopharma's total revenue changed from $0.00 in 2021 to $0.00 in 2024, a change of 0.0%.

Estrella Immunopharma's total liabilities were at $13.54 million at the end of 2025, a 351.9% increase from 2024, and a 734.1% increase since 2021.

In the past 4 years, Estrella Immunopharma's cash and equivalents has ranged from $40.80 thousand in 2022 to $2.48 million in 2023, and is currently $1.38 million as of their latest financial filing in 2025.

Over the last 3 years, Estrella Immunopharma's book value per share changed from -0.17 in 2021 to 0.16 in 2024, a change of -191.7%.

Related Companies

Financial statements for NASDAQ:ESLAW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLAW) Financials

Financials Breakdown Chart

Estrella Immunopharma Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLAW) Financials

Annual Income Statements for Estrella Immunopharma

Quarterly Income Statements for Estrella Immunopharma

Annual Cash Flow Statements for Estrella Immunopharma

Quarterly Cash Flow Statements for Estrella Immunopharma

Annual Balance Sheets for Estrella Immunopharma

Quarterly Balance Sheets for Estrella Immunopharma

Annual Metrics And Ratios for Estrella Immunopharma

Quarterly Metrics And Ratios for Estrella Immunopharma

Financials Breakdown Chart

Estrella Immunopharma Financials - Frequently Asked Questions

When does Estrella Immunopharma's fiscal year end?

How has Estrella Immunopharma's net income changed over the last 3 years?

What is Estrella Immunopharma's operating income?

How has Estrella Immunopharma's revenue changed over the last 3 years?

How much debt does Estrella Immunopharma have?

How much cash does Estrella Immunopharma have?

How has Estrella Immunopharma's book value per share changed over the last 3 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools